Compare Schlumberger NV (SLB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs GeneDx Holdings Corp — how do they compare? Schlumberger NV trades at $46.46 (market cap $69.36B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: Schlumberger NV is far larger — about 38.5× GeneDx Holdings Corp's market cap, and Schlumberger NV pays a 2.54% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SLB | WGS | |
|---|---|---|
Market Cap | $69.36B | $1.80B |
Sector | Energy | Technology |
52-Week High | $58.01 | $167.51 |
52-Week Low | $31.72 | $34.51 |
Enterprise Value | $77.58B | $1.80B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $46.67, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported revenue of $35.71 billion in 2025 with a net income margin of 9.26%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights strategic alliances for data center power solutions and new contract wins, signaling growth in digital and offshore segments.
The outlook is supported by strong analyst consensus with a $62.83 price target and 84.85% buy ratings, but risks include oil price volatility and execution challenges. The stock offers value with a P/E of 20.7 and ROE of 14.57%, though margin compression from 2024 warrants monitoring.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
